OncoMatch/Clinical Trials/NCT06168487
Telmisartan in Prostate Cancer
Is NCT06168487 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies Telmisartan for prostate cancer.
Treatment: Telmisartan — The goal of this clinical trial is to learn about the tolerability of telmisartan in patients with prostate cancer, but evidence for treatment efficacy will also be gathered.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: standard of care agent for prostate cancer (cabazitaxel, docetaxel, abiraterone, olaparib, rucaparib, talazoparib plus enzalutamide) — receiving or likely to receive
Participants must be receiving or likely to receive one of the following SOC agents for PC: cabazitaxel, docetaxel (alone or plus abiraterone) olaparib, rucaparib, or talazoparib plus enzalutamide
Cannot have received: angiotensin I receptor blocker
Angiotensin l receptor blocker use currently or within the 30 days prior to day 1, cycle 1.
Cannot have received: (lithium)
Patients on lithium therapy in any form
Cannot have received: (rituximab)
Patients who received rituximab ... within 30 days prior to first telmisartan dose on this study
Cannot have received: (amifostine)
Patients who received ... amifostine within 30 days prior to first telmisartan dose on this study
Cannot have received: (ramapril)
Patients on ramapril
Lab requirements
Blood counts
hb >10 gm/dl
Kidney function
serum creatinine ≤2.5 or estimated gfr >30 cc/min
Liver function
scot ≤3x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dartmouth Health · Lebanon, New Hampshire
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06168487 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior angiotensin I receptor blocker, , disqualifies patients from enrollment.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages